There is no cure for ALS today. Our view: the cure will not be one pill. It will be a matched combination, chosen by each person's genetic subtype, started before symptoms spread.
This is Cure Checker's editorial assessment of published evidence, not medical advice. Treatment decisions belong with a neurologist, ideally at a multidisciplinary ALS clinic.
Please read first. This is an AI-generated hypothesis, written by Cure Checker's AI from published research. It is speculation, not an established finding. It is not a recommendation, not a prediction that a cure exists, and not medical advice. No doctors or scientists have reviewed it, and it may be wrong. Never start, stop, change or delay any treatment because of it. Talk with your neurologist.
Could a blood or spinal-fluid test for cryptic proteins find people whose TDP-43 has started to fail, before or just as symptoms begin, even without a known ALS gene? And could treating them then, with a drug that corrects several TDP-43 splicing errors at once, slow the disease more than a single-target drug started later?
What would prove it wrong: if cryptic-protein levels do not rise early in ALS without a known gene, or if bringing them back down does not slow the disease.
Hypothesis written October 6, 2026. Cure Checker's AI will revisit it when major new evidence appears.
Newest first. Updated each morning as results, trial launches and papers are published.
An international task force from the International Alliance of ALS/MND Associations published consensus recommendations on genetic counseling and testing in ALS, with minimum and aspirational standards so that care is fair across countries with different resources. Access to genetic testing matters because some gene-targeted treatments and trials are limited to certain gene changes. It is expert guidance, not a trial result.
In 1,686 people with ALS from an Italian register, grouping people by the shape of their functional decline, not only its speed, found distinct patterns. Adding shape barely changed overall prediction accuracy (C-index 0.761 vs 0.755), but it separated people with different survival inside the same speed group. This is an analysis of past records and does not test any treatment.
A computer model over 10 years from a U.S. payer view found that care in a multidisciplinary ALS clinic added about 0.13 quality-adjusted life-years compared with standard neurology care, at about US$145,000 more. That is far above usual cost-effectiveness limits, so it was cost-effective in only 0.1% of simulations. The model used published numbers and assumed a survival benefit, so it is not a trial and does not say the care is unhelpful.
In a Danish cohort of 165 people who later developed ALS and 332 matched controls, higher blood neurofilament light (a nerve-damage marker) was linked to about 1.6 times the odds of ALS. The link was strongest within 5 years of diagnosis (3.8 times) and was not statistically significant more than about 14.6 years before. The marker is not specific to ALS, and the authors say screening everyone would be premature.
German researchers published the plan for a placebo-controlled trial of rituximab, a drug that removes B cells (antibody-making immune cells), in 52 people with ALS who also take riluzole. Treatment would run 52 weeks, with the main measure being change in the ALS function score at week 79. This is a published trial plan, not results, and it does not show the drug helps.
Clene says it has submitted a new drug application asking the FDA for accelerated approval of its oral drug CNM-Au8. It rests mainly on lower blood neurofilament light and analyses linking that drop to survival. Neither the RESCUE-ALS trial nor the HEALEY trial met its main goal. The FDA has not yet said whether it will accept the application, so this is not an approval.
In 42 people with ALS in Italy, two stool-bacteria transplants given through a tube missed the main goal: a rise in a type of calming immune cell (Tregs) was not statistically clear (44% vs 20%, p = .21). Symptom scores declined a little more slowly with the transplant (0.76 vs 1.07 points a month), but this was a secondary, exploratory result in a small trial. The authors say it raised no major safety concerns.
McMaster University researchers (Nature Communications) found that a single flu infection before symptoms started made disease progress faster in a mouse model of inherited (SOD1) ALS. Blocking immune cells called microglia, or giving an antiviral drug, slowed it. Results with the COVID virus were similar. It was done in only one mouse model, so it does not show the same thing happens in people.
A $26 million NIH-funded project led by the University of Pennsylvania will follow about 330 people over 45 who carry the C9orf72 gene change, the most common inherited cause of ALS and FTD. It will use cognitive and motor tests, MRI and body-fluid tests to find early signs. Enrollment begins in December. This is a natural-history study, not a treatment trial.
News report: veterans are about twice as likely to develop ALS, and researchers are still looking for the reasons. The ALS Society of Canada is asking for $50 million in federal research funding. This is a news report, not a new study.
No clinical benefit in ALS and more liver-enzyme rises than placebo. Further development in ALS is not warranted.
The last patient has finished the placebo-controlled part of the trial. Top-line results are expected by the end of 2026. No results have been reported yet.
Mayo Clinic reports early results in a single patient with a rare inherited form of ALS. After six doses of an antisense drug given into spinal fluid, a blood marker of nerve injury (neurofilament light) fell by up to 50%, and breathing, thinking and physical function stayed stable or improved slightly. One patient only, so it does not show the drug works.
First ALS patients dosed with a nasal anti-CD3 antibody meant to calm brain inflammation. Underway.
Extends federal funding for expanded access, biomarker and natural-history research through 2031. Sent to the President for signature.
Met primary endpoint: significant improvement in function and survival in FUS-ALS, with favorable safety. First successful FUS-ALS trial.
Passed 100 participants enrolled. Tests an immune-modulating combo (low-dose IL-2 + CTLA4-Ig). Full enrollment expected in 2026.
Missed its primary goal on biomarkers after six weeks. Exploratory signs of slower motor decline; more analyses coming.
Despite hitting its biological target (the eIF2B pathway), 200 mg/day did not slow ALS progression.
Immune cells in the spinal cord actively destroy motor neurons in ALS mice. A new immune target.
11 studies: occupational pesticide exposure linked to ~60% higher ALS risk, up to ~3× at high exposure; signal seen in men.
Enrollment completed; topline results moved up to Q2 2027.
First oral drug designed to break up aggregated TDP-43 enters human testing.
Pivotal trial in early, rapidly progressing ALS is enrolling, including sites in Canada.
FDA feedback supports an accelerated-approval application based on NfL and survival data; filing planned Q3 2026.
Primary endpoint not met; exploratory analyses hint at a survival benefit in subgroups.
Single dose reduced neurofilament light chain by 81% in SOD1-ALS with favorable safety.
Antibody to misfolded SOD1: lower nerve-damage markers, delayed ventilation and survival benefit in sporadic and SOD1-ALS.
2.23-point slower decline on ALSFRS-R vs placebo and 9.4% NfL reduction; safety goals met.
Motor neurons lose a selective protein clean-up system they rely on heavily, a possible new drug target.
About 25% stabilized or improved over 3–5 years; survival near 5 years in SOD1-ALS.
The clearest wins come from drugs that silence a single faulty gene. These help a minority of patients with that gene, but the benefit is the largest ALS has ever seen.
The FUSION trial met its main goal (p = 0.0005), improving function and survival together over 72 weeks. It is the first placebo-controlled proof that targeting the cause of a genetic ALS works. FDA filing planned; early access program being set up.
After 3–5 years on the drug, about 1 in 4 people stabilized or improved in strength and breathing, and survival reached nearly 5 years versus a typical 2–3. Doctors called that "unheard of" in SOD1-ALS.
An antibody against misfolded SOD1. Lowered nerve-damage markers (NfL, pNfH), delayed the need for ventilation, and showed survival benefit in both sporadic ALS and SOD1 carriers. Small trial; needs Phase 3.
A combination of two existing drugs (ciprofloxacin + celecoxib). Slowed decline by 2.23 points on the ALS function scale versus placebo and cut NfL by 9.4%.
Gold nanocrystals that boost nerve-cell energy. FDA said biomarker and survival data may support accelerated approval; confirmatory Phase 3 to start in 2027.
A single dose cut neurofilament light chain, a marker of nerve damage, by 81%, with good safety. Early, but a strong biological signal.
| Drug | For | What it does |
|---|---|---|
| Riluzole (1995) | All ALS | Lowers glutamate over-excitation. Adds roughly 2–3 months of survival on average. |
| Edaravone (IV 2017, oral 2022) | All ALS | Antioxidant. Modest slowing of functional decline in some patients. |
| Tofersen (2023) | SOD1-ALS (~2%) | Silences the faulty SOD1 gene. Largest benefit of any approved ALS drug. |
| Rozebalamin (Japan, 2024) | Early ALS | Ultra-high-dose methylcobalamin (B12) by injection. Not FDA approved. |
No supplement prevents or cures ALS. Some have real evidence behind them, many do not. We rate each by the strength of human evidence.
Large Harvard cohorts linked higher omega-3 intake, especially ALA, to lower ALS risk and slower progression. Food sources are preferred.
Pooled data from about 1 million people tied long-term vitamin E intake to lower risk. Nuts, seeds and leafy greens are good sources.
Diets rich in antioxidants and carotenoids (orange and dark-green produce) are associated with lower risk and better function.
Not a supplement, but the best-supported prevention step. Use protective gear if you work with farm or lawn chemicals.
Weight loss predicts faster decline. In the LIPCAL-ALS trial, extra calories helped fast-progressing patients live longer. Work with a dietitian.
Japan's JETALS trial slowed decline in early ALS using 50 mg injections twice weekly. Store-bought oral B12 is not the same dose or route.
Mixed results. Reasonable to correct a measured deficiency for bone and muscle health.
Small studies suggest relief of stiffness, cramps, appetite and sleep. Discuss interactions with your care team.
Each was tested in controlled ALS trials and did not slow the disease.
Be careful: unregulated "stem cell" clinics and high-dose supplement stacks can be costly and harmful. Tell your neurologist about everything you take.
Centers recognized for expertise in this condition, and communities of people living with it.
Recognized for leading the HEALEY ALS Platform Trial, which tests several possible ALS treatments in one study. The registry lists a Mass General investigator as the lead sponsor.
Recognized as a Treatment Center of Excellence by the ALS Association and as a Certified ALS Center by the Muscular Dystrophy Association, according to Emory.
Designated an ALS Association Certified Treatment Center of Excellence after meeting that program's care standards, according to the university.
Named an ALS Association Certified Treatment Center of Excellence, as reported in 2014.
Described by the Precision ALS research consortium as the Dutch national centre of expertise on ALS.
These are centers recognized for expertise in this condition, not a ranking, and Cure Checker does not endorse or rate any facility. Outcomes depend on the individual. Ask your doctor which center fits your situation.
You don't have to face ALS alone. These groups connect patients, families and caregivers with people who understand. Most are free.
In-person and virtual groups across the U.S., including a nationwide online group for caregivers.
Find a group ↗Free weekly virtual support groups run by a patient-led nonprofit.
Join a group ↗Free online support groups held throughout the year.
See schedule ↗Professionally led monthly groups, plus ALStogether, a community hub on Slack founded by Brooke Eby.
Learn more ↗A long-running online discussion forum for patients, caregivers and families.
Visit forum ↗The UK charity's online forum for people affected by motor neurone disease (the UK name for ALS).
Visit forum ↗Share your experience, track your health and compare notes with others living with ALS.
Join ↗An open Reddit community for questions, updates and support.
Open on Reddit ↗Many private ALS and caregiver groups. This link searches Facebook (a login is required).
Search Facebook ↗Many ALS groups also welcome caregivers, family and people who are grieving. Les Turner and ALS Network run groups for specific needs, including Spanish speakers, veterans and LGBTQIA+ people.
Before you join: support groups share experiences, not medical advice. Check anything about treatment with your doctor. Think about your privacy, because Reddit and many forums are public, and never share passwords or financial details. Cure Checker isn't affiliated with these groups.
Regulators don't all agree. Some treatments are approved in Japan or Korea and nowhere else, and some countries let patients get drugs years before approval. Here is who allows what, how that changed over time, and where trials are recruiting today.
| Treatment | U.S. | EU | UK | Canada | Japan | S. Korea | China | Australia | Switz. |
|---|---|---|---|---|---|---|---|---|---|
| RiluzoleAll ALS | 1995 | 1996 | 1996 | Yes | Yes | Yes | Yes | Yes | Yes |
| EdaravoneAll ALS | 2017 | Withdrawn | — | 2018 | 2015 | 2015 | 2019 | 2023 | 2019 |
| TofersenSOD1-ALS | 2023 | 2024 | 2025 | 2025 | 2024 | — | Trial | 2026 | — |
| Ultra-high-dose B12 (Rozebalamin)Early ALS | — | — | — | — | 2024 | — | — | — | — |
| Lenzumestrocel (Neuronata-R)Stem-cell therapy | — | — | — | — | — | 2014, conditional | — | — | — |
| AMX0035 (Relyvrio / Albrioza)All ALS | 2022, pulled 2024 | Rejected 2023 | — | 2022, pulled 2024 | — | — | — | — | — |
| MasitinibAll ALS | Trial | Rejected 2024 | — | Rejected 2024 | — | — | — | — | — |
50 mg methylcobalamin injected twice a week. Japan's JETALS Phase 3 showed slower decline in early ALS. U.S. patients have sought it through named-patient import programs.
The patient's own bone-marrow stem cells, injected into the spinal fluid. Phase 3 missed its main goal overall but helped slow progressors. Korea renewed its approval in May 2026.
Both countries gave SOD1-ALS patients tofersen more than a year before the U.S. approved it. Their real-world results now add to the evidence. Ask your neurologist about expanded-access programs.
ALS is a "multi-hit" disease. Genes, environment, and age add up until motor neurons cross a tipping point. In almost every case, that tipping point involves one protein: TDP-43.
Live numbers and the newest entries from the world's main trial registries and medical databases. Most of this loads fresh each time you open the page.
Loading live data from ClinicalTrials.gov…
Loading…
Loading…
Loading…
| Medicine | Brand | FDA application | Original approval |
|---|
From Drugs@FDA via FDA's openFDA service. Some older brands are missing from FDA's open data, and newly approved drugs can take a few weeks to appear. An approval may be for a different disease than this one.
The WHO's ICTRP gathers trials from registries worldwide, including China, Japan, India, Iran, Australia and Brazil. Cochrane CENTRAL and OpenMD don't allow automated access, so they're linked here for you to search directly.
These organizations exist to help families affected by ALS pay for care and costs. Funds are limited and rules vary, so contact each one directly.
Pays back some costs insurance doesn't cover, such as respite care, adaptive devices, certain medical costs and equipment, and home changes. Grants depend on available funds.
See Flex Grants ↗A limited number of grants toward respite or home health care, prescription copays and medical equipment that insurance doesn't cover. Subject to available funds.
See the program ↗Pays back costs insurance doesn't cover, such as respite care, clinic travel, home or vehicle changes and communication devices. Funds are limited and may run out.
See the program ↗Grants for home changes, speech devices, power wheelchairs, or respite and home care. Subject to available funds.
See the program ↗Pays for up to 80 hours a year of respite care from an agency, so family caregivers can take a short break.
See the program ↗Grants to help with costs insurance doesn't fully cover, such as wheelchairs, stair lifts, bathroom changes and speech devices.
See the program ↗Need-based grants toward equipment, home changes, respite care, assistive technology and rides to the clinic.
See grant programs ↗Small grants so children living with a family member who has ALS can join activities like tutoring, camps and lessons. Ask your care manager.
Learn more ↗Grants and programs for equipment and technology, including help with communication-device copays and seat elevators.
Read the FAQ ↗One-time grants for respite care. A limited number of applicants are picked by random drawing each quarter.
See the grant ↗Quality-of-life grants (for example home access, respite care or kids' activities) and college scholarships for children of people with ALS. Applications open in cycles.
See programs ↗The UK charity's grants for everyday living, technology, wellbeing and cost-of-living help such as bills and food. They don't need to be repaid.
Read the guidance ↗Helps pay prescription copays for ALS medicines, or Medicare Part B premiums. The fund was listed as open on October 6, 2026, but funds can run out.
Check fund status ↗Before you apply: Cure Checker does not run, verify or endorse these organizations, and being listed is not a promise of help. Funds are limited and rules change, so confirm eligibility and details with each organization. Be careful of anyone who asks for payment up front or for your bank login to 'release' a grant.
Everything this report is based on, grouped by section. Checked October 5, 2026.
The vitamin D, cannabis, and creatine / CoQ10 / lithium summaries reflect the general trial record and don't yet have individual citations here. Expert care centers: Facility designations come from each center's own page or news reports because the ALS Association's directory could not be opened; the Healey Center's ALS Association certification was not confirmed. Financial help: checked October 6, 2026. Team Gleason's site blocks automated reading, so its card is based on its search-indexed FAQ and recent news; Live Like Lou's quality-of-life grants were between application cycles; the ALS Association programs are run by individual states, and the Massachusetts page does not give application dates.